Clinical Trials Logo

Clinical Trial Summary

This is a phase 2 randomized study for High risk localized prostate cancer (T3 to T4 disease and/or PSA > 20 and/or Gleason score ≥ 8) without evidence of distant and nodal metastasis. Patient will be randomized to:Arm 1 - Conventional IMRT RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes). - 38 fractions of daily treatment, Monday to Friday or Arm 2 SBRT - RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) - 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy (detail as below)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03938649
Study type Interventional
Source Chinese University of Hong Kong
Contact Darren MC POON, FHKCR
Phone 3505 2128
Email mc_poon@clo.cuhk.edu.hk
Status Recruiting
Phase Phase 2
Start date May 15, 2019
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06006104 - Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Recruiting NCT03936218 - Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer Phase 3
Completed NCT02234089 - Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Completed NCT01078545 - Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) N/A
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Recruiting NCT05942001 - Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1
Active, not recruiting NCT04117594 - Whole Body Magnetic Resonance Imaging Study
Not yet recruiting NCT06369246 - PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer Phase 2
Completed NCT01383863 - A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
Completed NCT03651271 - Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer Phase 2
Active, not recruiting NCT05590793 - Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Phase 3
Recruiting NCT06095089 - A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer Phase 1
Active, not recruiting NCT02787837 - PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
Active, not recruiting NCT02362620 - PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
Recruiting NCT05800665 - A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer Phase 1
Completed NCT00871585 - Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide N/A
Active, not recruiting NCT02922218 - PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
Not yet recruiting NCT06335914 - Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer N/A
Terminated NCT03577028 - Study of HPN424 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Terminated NCT03971110 - A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. Phase 4